{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06265688",
            "orgStudyIdInfo": {
                "id": "CTMX-2051-101"
            },
            "organization": {
                "fullName": "CytomX Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "First In Human Study of CX-2051 in Advanced Solid Tumors",
            "officialTitle": "An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "first-in-human-study-of-cx-in-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-11-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-03-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-12",
            "studyFirstSubmitQcDate": "2024-02-12",
            "studyFirstPostDateStruct": {
                "date": "2024-02-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-06",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-07",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "CytomX Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 in adult participants with advanced solid tumors.",
            "detailedDescription": "The study is comprised of 2 parts. Part 1 involves CX-2051 dose escalation to identify the maximum tolerated dose (MTD) of CX-2051. Part 2 (dose expansion) will further assess safety and tolerability as well as preliminarily assess antitumor activity of CX-2051 in indication-specific expansion cohorts."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor, Adult"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 124,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "CX-2051",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: CX-2051"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "CX-2051",
                    "description": "Investigational drug monotherapy",
                    "armGroupLabels": [
                        "CX-2051"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety and tolerability of CX-2051",
                    "description": "The number of participants experiencing a dose-limiting toxicity (DLT) as defined in the protocol, AEs (adverse events), and treatment-emergent adverse events (TEAEs) at any dose level",
                    "timeFrame": "44 months"
                },
                {
                    "measure": "Determine the recommended Phase 2 dose (RP2D)",
                    "description": "The number of participants experiencing a dose-limiting toxicity (DLT) as defined in the protocol, AEs (adverse events), and treatment-emergent adverse events (TEAEs) at any dose level",
                    "timeFrame": "44 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective response rate (ORR)",
                    "description": "ORR defined as the proportion of participants who achieve a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator assessment",
                    "timeFrame": "60 months"
                },
                {
                    "measure": "Duration of response (DOR)",
                    "description": "DOR defined as the time from the first documentation of confirmed CR or PR (based on RECIST v1.1) to the first documentation of disease progression or death due to any cause on study, whichever occurs first.",
                    "timeFrame": "60 months"
                },
                {
                    "measure": "Progression-free survival (PFS)",
                    "description": "PFS defined as the time from the first dose of study intervention to the date of first documentation of objective tumor progression (based on RECIST v1.1) or death due to any cause, whichever occurs first.",
                    "timeFrame": "60 months"
                },
                {
                    "measure": "Disease control rate (DCR)",
                    "description": "DCR defined as the proportion of participants with confirmed CR, PR, or stable disease (SD) as per RECIST v1.1 by Investigator assessment.",
                    "timeFrame": "60 months"
                },
                {
                    "measure": "Duration of disease control (DODC)",
                    "description": "DODC defined as the time from the first documentation of confirmed CR, PR, or SD (based on RECIST v1.1) to the first documentation of disease progression or death due to any cause on study, whichever occurs first.",
                    "timeFrame": "60 months"
                },
                {
                    "measure": "Overall survival (OS)",
                    "description": "OS defined as the time from the first dose of study intervention to death due to any cause",
                    "timeFrame": "60 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Measurable disease per RECIST v1.1\n* Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue\n* Additional inclusion criteria may apply\n\nExclusion Criteria:\n\n* Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated\n* Known active central nervous system (CNS) involvement by malignancy\n* Systemic anticancer treatment, radiotherapy, or investigational agent(s) within 14 days prior to C1D1\n* Previous treatment with antibody-drug conjugates (ADCs) with Topo-I inhibitor payload\n* Major surgery (requiring general anesthesia) within 4 weeks prior to C1D1\n* Elevated baseline laboratory values\n* Serious concurrent illness\n* Pregnant or breast feeding\n* Additional exclusion criteria may apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Karen Deane",
                    "role": "CONTACT",
                    "phone": "650-515-3185",
                    "email": "clinicaltrials@cytomx.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Monika Vainorius, MD",
                    "affiliation": "CytomX Therapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Dana-Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Carolina BioOncology Institute, PLLC",
                    "status": "RECRUITING",
                    "city": "Huntersville",
                    "state": "North Carolina",
                    "zip": "28078",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.41069,
                        "lon": -80.84285
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute, LLC",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        }
    },
    "hasResults": false
}